Dai ichi Life Insurance Company Ltd Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

Dai ichi Life Insurance Company Ltd acquired a new position in Hologic, Inc. (NASDAQ:HOLX) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 9,299 shares of the medical equipment provider’s stock, valued at approximately $757,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Prentiss Smith & Co. Inc. lifted its stake in shares of Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after purchasing an additional 130 shares in the last quarter. Covestor Ltd lifted its position in Hologic by 23.8% during the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after acquiring an additional 133 shares in the last quarter. First Horizon Advisors Inc. increased its position in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its holdings in Hologic by 20.3% in the second quarter. Massmutual Trust Co. FSB ADV now owns 831 shares of the medical equipment provider’s stock valued at $62,000 after purchasing an additional 140 shares during the last quarter. Finally, Empirical Finance LLC boosted its holdings in Hologic by 1.8% in the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock valued at $690,000 after purchasing an additional 147 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Trading Up 0.6 %

NASDAQ:HOLX opened at $79.44 on Friday. The stock has a fifty day simple moving average of $80.28 and a 200 day simple moving average of $78.42. The firm has a market capitalization of $18.45 billion, a price-to-earnings ratio of 23.86, a price-to-earnings-growth ratio of 2.51 and a beta of 0.98. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period last year, the firm posted $0.89 earnings per share. Sell-side analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Raymond James upped their target price on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. UBS Group upped their price target on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Royal Bank of Canada lifted their price target on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Mizuho cut their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. increased their price target on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.